The selank semax nootropic pairing occupies a strange corner of the cognitive-enhancement world: two intranasal peptides approved as medicines in Russia since the 1990s, widely discussed on biohacking forums, and almost entirely absent from Western pharmacopoeias. Walk into a pharmacy in Moscow and you can buy Semax over the counter for stroke recovery. Walk into one in Boston and the pharmacist has likely never heard of it.
Both compounds were born in the same Soviet-era research program at the Russian Academy of Medical Sciences, and both share a pattern we have seen repeatedly in our coverage of Russian peptide science: intriguing mechanistic rationale, a long trail of domestic clinical publications, and a near-total gap in Western randomized trials. This deep dive examines what the evidence actually supports, what it does not, and why Selank and Semax remain pharmacological curiosities rather than approved Western therapies.
⚕️ Regulatory notice. Selank and Semax are not FDA-approved in the United States or authorized by the EMA in Europe. They are registered medicines only in Russia and a handful of CIS countries (Belarus, Ukraine, Georgia). Sales as "research chemicals" in Western markets are legally ambiguous and are not quality-controlled. Nothing in this article constitutes medical advice.
What Are Selank and Semax?
Selank and Semax are short synthetic peptides developed at the M. V. Lomonosov Moscow State University and the Institute of Molecular Genetics of the Russian Academy of Sciences, primarily under the leadership of Nikolai Myasoedov's group during the late 1980s and 1990s. Both are what pharmacologists call "designed analogs" — they take a naturally occurring peptide fragment and bolt on a stabilizing tail to make it resist enzymatic degradation long enough to cross the nasal mucosa and reach the brain.
Selank is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin, an immunomodulatory peptide fragment of the heavy chain of immunoglobulin G. Natural tuftsin has a plasma half-life measured in minutes; the Pro-Gly-Pro extension gives Selank hours of stability. It was registered in Russia in 2004 for generalized anxiety disorder.
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) corresponding to fragment 4–10 of adrenocorticotropic hormone (ACTH), again with a Pro-Gly-Pro tail. Unlike full ACTH, the 4–10 fragment has no hormonal activity on the adrenal cortex but retains behavioral and neurotrophic effects. Semax was registered earlier (1994) and is sold in Russia for ischemic stroke, transient ischemic attack, cognitive disorders, and optic nerve atrophy.
Both are administered as intranasal drops, which bypasses first-pass metabolism and leverages the olfactory pathway for partial direct-to-brain delivery.
Mechanism of Action
The proposed mechanism that gets cited most often in both Russian and Western literature is modulation of brain-derived neurotrophic factor (BDNF) and its downstream signaling. A frequently referenced study by Agapova et al. (2007) and later work from Dolotov et al. (2006) reported that Semax rapidly increases BDNF and its tyrosine kinase receptor TrkB in the hippocampus of rats within 3 hours of intranasal dosing. Selank has been shown to similarly upregulate BDNF expression in limbic structures, though effect sizes vary considerably between studies.
Beyond BDNF, the proposed mechanisms include:
- Enkephalinase inhibition — Selank appears to slow the degradation of endogenous enkephalins, which may contribute to its reported anxiolytic effect without the sedation, tolerance, or withdrawal seen with benzodiazepines.
- Modulation of serotonergic and GABAergic tone — rat studies show changes in serotonin turnover and GABA receptor expression after Selank administration.
- Neuroprotection via suppression of oxidative stress and inflammatory cytokines — the Semax stroke indication leans heavily on this rationale.
- Expression changes in immediate-early genes (c-Fos, c-Jun) in cortical and hippocampal regions.
The story is mechanistically plausible. It is also almost entirely built on rodent experiments performed by the same small network of Russian laboratories, and replication by independent Western groups is sparse.
The Clinical and Experimental Evidence
This is where honest assessment is required. The Russian literature on Selank and Semax is not small — there are dozens of clinical reports — but the methodology rarely meets the standards that Western regulators would demand for approval.
Selank for anxiety. The pivotal Russian trial that underpins Selank's registration was conducted by Zozulya et al. (2008) and reported that Selank was non-inferior to medazepam (a benzodiazepine) in patients with generalized anxiety disorder. The study enrolled around 60 patients, was open-label rather than double-blind, and used clinician-rated scales without the rigor of a modern ICH-GCP trial. A later paper by Medvedev et al. (2015) reported changes in gene expression in the blood of anxious patients treated with Selank, which is interesting mechanistic data but does not substitute for a proper efficacy RCT.
Semax for stroke. A series of Russian trials led by Gusev and Skvortsova (1997, 2003) reported improved neurological recovery in ischemic stroke patients treated with Semax within the first days of the event. These studies are the basis for its stroke indication in Russia. They were not blinded in the modern sense, used varied outcome scales, and have never been replicated in large Western stroke trials.
Semax for cognition. Smaller studies — often cited as Kaplan et al. (1996) and Ashmarin et al. (1997) — reported improvements in attention and memory in healthy volunteers and in patients with mild cognitive disorders. Sample sizes were in the 20–40 range. None are the kind of registration-grade RCT that would support a nootropic claim in the US or EU.
Western evidence gap. A PubMed search yields fewer than a dozen independent Western publications on either peptide as of 2026, and none are randomized controlled trials in humans. This is the same structural problem we encountered in our Epitalon evidence review: the molecules exist, mechanism papers exist, and single-center clinical reports exist — but the independent replication that would justify global adoption does not.
Applications
In Russia, where both peptides are registered medicines, the labeled and commonly prescribed uses are:
- Selank: generalized anxiety disorder, asthenic syndromes, adjustment disorders.
- Semax: acute ischemic stroke, transient ischemic attack, post-stroke cognitive impairment, optic nerve atrophy, and (in pediatric formulations) attention and learning difficulties.
Outside Russia, the use is almost entirely off-label and driven by the biohacker and nootropic communities. Users typically report:
- Reduced situational anxiety without sedation (Selank).
- Subjective improvements in focus, verbal fluency, and mental endurance (Semax).
- Fast onset — within 15–30 minutes of intranasal dosing.
- No meaningful withdrawal on discontinuation.
Compared to the Western nootropic landscape — modafinil, the racetam family (piracetam, aniracetam, phenylpiracetam), caffeine-L-theanine stacks, and microdosed stimulants — Selank and Semax occupy a distinct "peptide-neurotrophic" niche. Phenylpiracetam, interestingly, is another Russian-developed compound with similar evidence-quality issues.
Connection to Gene Editing
At first glance, a nootropic peptide has nothing to do with gene editing. Look closer and the connection becomes one of the more interesting crossovers in current neuroscience.
Both Selank and Semax are proposed to work by changing gene expression in the brain — not by altering DNA sequence, but by modulating the transcription of BDNF, TrkB, c-Fos, and a suite of neurotrophic and inflammatory genes. The Medvedev et al. (2015) Selank paper explicitly framed the drug as a "modulator of the transcriptome." That puts these peptides in the same conceptual bucket as epigenetic therapeutics — small molecules that rewire which genes are active without touching the underlying code.
The longer-term gene-editing angle is this: if the therapeutic effects of Selank and Semax really do flow from upregulating BDNF and its receptor, then newer tools such as CRISPR activation (CRISPRa) — using catalytically dead Cas9 fused to transcriptional activators — could in principle achieve the same BDNF upregulation more precisely and more durably than a peptide you have to sniff every day. Early academic work in mice has already used CRISPRa to boost BDNF in specific brain regions as a model for depression and neurodegeneration research. If you want the foundation, our complete CRISPR guide covers both classical editing and the activation variants.
And for readers following the aging thread: BDNF decline is one of the best-characterized molecular signatures of brain aging, tying directly into the "altered intercellular communication" and "loss of proteostasis" themes in our hallmarks of aging explainer.
Limitations and Regulatory Status
The honest summary is that Selank and Semax are interesting, not proven. The specific limitations worth naming:
- Evidence concentration. Nearly all clinical data comes from a small number of Russian academic groups with institutional ties to the developers.
- Trial design. Open-label, small sample sizes, non-standard outcome measures, and limited reporting of adverse events by modern standards.
- Independent replication. Almost none in Western literature.
- Quality control. Material sold as "research chemicals" online is not manufactured under GMP conditions. Peptide purity, endotoxin levels, and actual content have been questioned in multiple independent analyses of grey-market products.
- No FDA pathway. Neither peptide has an active IND (Investigational New Drug) application in the United States. The FDA's 2023 restrictions on peptide compounding under 503A further tightened legal access.
- Long-term safety unknown. Because the peptides have only been used at scale in one country for a few decades, we have limited data on chronic administration, pregnancy outcomes, or interactions with Western psychiatric medications.
If you are in the US or EU, purchasing Selank or Semax for personal use sits in a legally grey zone. Possession for personal use is not typically prosecuted, but importation and sale are another matter.
FAQ
Are Selank and Semax the same thing?
No. They come from the same Russian research program and share a stabilizing Pro-Gly-Pro tail, but Selank is derived from tuftsin (an immune peptide) and is used primarily for anxiety, while Semax is derived from ACTH 4–10 and is used primarily for stroke recovery and cognition.
Is there any Western clinical trial data?
As of 2026, there are no completed randomized controlled trials of either peptide in the US or EU that meet modern registration standards. Almost all clinical evidence comes from Russian academic groups.
How are they administered?
Both are given as intranasal drops. Oral administration destroys them in the gut, and the nasal route allows some direct-to-brain delivery via the olfactory pathway.
Do they cause withdrawal or dependence?
Russian reports and biohacker user reports converge on "no meaningful withdrawal," which is one of the most frequently cited advantages over benzodiazepines for the Selank anxiety indication. Long-term dependence data is limited.
Are they legal in the US?
They are not FDA-approved, not scheduled as controlled substances, and not on the FDA's 503A bulks list. Products sold online are labeled "research use only" and the legal status of personal importation is ambiguous. This is not legal advice.
Could CRISPR replace them one day?
Conceptually yes, if the therapeutic mechanism really is BDNF upregulation, CRISPR activation systems targeting the BDNF promoter could in principle achieve more durable effects — but this remains early preclinical research, not a clinical option.
